Month: November 2022

On February 29, 2020, Okano, Hideyuki; Yasuda, Daisuke; Fujimori, Koki; Morimoto, Satoru; Takahashi, Shinichi published an article.Quality Control of 4-((2,4-Dichloro-5-methoxyphenyl)amino)-6-methoxy-7-(3-(4-methylpiperazin-1-yl)propoxy)quinoline-3-carbonitrile The title of the article was Ropinirole, a New ALS Drug Candidate Developed Using iPSCs. And the article contained the following:

A review. Induced pluripotent stem cells (iPSCs) are increasingly used in the study of disease mechanisms and the development of effective disease-modifying therapies for neurodegenerative diseases, including amyotrophic lateral sclerosis (ALS). Recently, three candidate anti-ALS drugs-ropinirole (ROPI), retigabine, and bosutinib-have been identified in iPSC-based drug screens and are now being evaluated in clin. trials for safety and effectiveness. We review the preclin. data, clin. research design, and rationale for ROPI as an anti-ALS drug candidate compared with those of the other two drugs. We also discuss the use of iPSCs for understanding and monitoring treatment response as well as for new insights into the development of new drugs and therapeutic interventions for major neurodegenerative diseases. The experimental process involved the reaction of 4-((2,4-Dichloro-5-methoxyphenyl)amino)-6-methoxy-7-(3-(4-methylpiperazin-1-yl)propoxy)quinoline-3-carbonitrile(cas: 380843-75-4).Quality Control of 4-((2,4-Dichloro-5-methoxyphenyl)amino)-6-methoxy-7-(3-(4-methylpiperazin-1-yl)propoxy)quinoline-3-carbonitrile

The Article related to ropinirole als drug candidate ipscs review, amyotrophic lateral sclerosis, disease modeling, drug repositioning, induced pluripotent stem cells, ropinirole, Placeholder for records without volume info and other aspects.Quality Control of 4-((2,4-Dichloro-5-methoxyphenyl)amino)-6-methoxy-7-(3-(4-methylpiperazin-1-yl)propoxy)quinoline-3-carbonitrile

Referemce:
Piperazine – Wikipedia,
Piperazines – an overview | ScienceDirect Topics

Diamandas, Alexander; Razon, Mikhail R.; Ramirez-Arcos, Sandra; Brassinga, Ann Karen C. published an article in 2021, the title of the article was The virulence of S. marcescens strains isolated from contaminated blood products is divergent in the C. elegans infection model.Recommanded Product: 86393-32-0 And the article contains the following content:

Bacterial contamination of platelet concentrates (PCs) can occur during blood donation or PC processing, necessitating routine screening to identify contaminated products in efforts to prevent adverse transfusion reactions in recipient patients. Serratia marcescens is a common bacterial contaminant, and its resilient nature coupled with genetic promiscuity imbue this environmental bacterium with resistance to disinfectants and antibiotics enhancing bacterial virulence. In this study, we aim to understand adaptive survival mechanisms through genetic characterization of two S. marcescens strains, CBS11 and CBS12, isolated from PCs by Canadian Blood Services. Genomic analyses of the two strains indicated that CBS11 has one chromosome and one plasmid (pAM01), whereas CBS12 has no plasmids. Phylogenetic analyses show that CBS11 and CBS12 are non-clonal strains, with CBS11 clustering closely with clin. strain CAV1492 and less so with environmental strain PWN146, and CBS12 clustering with a clin. strain AR_0027. Interestingly, pAM01 was most closely related to PWN146p1, a plasmid found in S. marcescens PWN146 strain associated with pinewood nematode Bursaphelenchus xylophilus. Lastly, the genomic diversity of CBS11 and CBS12 was not reflected in the antibiotic resistance profiles as they were remarkably similar to one another, but was reflected in the virulence phenotypes assessed in the Caenorhabditis elegans nematode infection model, with CBS11 being more virulent then CBS12. Taken together, we suggest that S. marcescens environmental isolates that feature evolutionary diverse genomics are better equipped to adapt and thrive in varied environments, such as that of PCs, and therefore is as much of a concern as multi-drug resistance for human infection potential. The experimental process involved the reaction of 1-Cyclopropyl-6-fluoro-4-oxo-7-(piperazin-1-yl)-1,4-dihydroquinoline-3-carboxylic acid hydrochloride hydrate(cas: 86393-32-0).Recommanded Product: 86393-32-0

The Article related to serratia marcescens contaminated blood caenorhabditis elegans infection, c. elegans, genomic analyses, platelet concentrates, serratia macrescens, virulence, Placeholder for records without volume info and other aspects.Recommanded Product: 86393-32-0

Referemce:
Piperazine – Wikipedia,
Piperazines – an overview | ScienceDirect Topics

On December 31, 2021, Smith, Stephanie M.; Sabnis, Himalee S.; Lewis, Rebecca Williamson; Effinger, Karen E.; Bergsagel, John; Patterson, Briana; Mertens, Ann; Sakamoto, Kathleen M.; Schapira, Lidia; Castellino, Sharon M. published an article.SDS of cas: 380843-75-4 The title of the article was Patterns of surveillance for late effects of BCR-ABL tyrosine kinase inhibitors in survivors of pediatric Philadelphia chromosome positive leukemias. And the article contained the following:

Targeted anticancer therapies such as BCR-ABL tyrosine kinase inhibitors (TKIs) have improved outcomes for chronic myeloid leukemia (CML) and Philadelphia chromosome-pos. acute lymphoblastic leukemia (Ph + ALL). However, little is known about long-term risks of TKIs in children. Exposure-based survivorship guidelines do not include TKIs, thus surveillance practices may be variable. We retrospectively examined surveillance for cardiac and endocrine late effects in children receiving TKIs for Ph + leukemias, diagnosed at < 21 years between 2000 and 2018. Frequency of echocardiogram (ECHO), ECG (ECG), TSH (TSH), dual-energy x-ray absorptiometry (DXA), and bone age testing were abstracted. Descriptive statistics were stratified by leukemia type. 66 Patients (CML n = 44; Ph + ALL n = 22) met inclusion criteria. Among patients with CML, ≥1 evaluation was done: ECHO (50.0%), ECG (48.8%), TSH (43.9%), DXA (2.6%), bone age (7.4%). Among patients with Ph + ALL, ≥1 evaluation was done: ECHO (86.4%), ECG (68.2%), TSH (59.1%), DXA (63.6%), bone age (44.4%). Over a median 6.3 and 5.7 years of observation, resp., 2% of patients with CML and 57% with Ph + ALL attended a survivorship clinic. Despite common exposure to TKIs in survivors of Ph + leukemias, patterns of surveillance for late effects differed in CML and Ph + ALL, with the latter receiving more surveillance likely due to concomitant chemotherapy exposures. Targeted therapies such as TKIs are revolutionizing cancer treatment, but surveillance for late effects and referral to survivorship clinics are variable despite the chronicity of exposure. Evidence based guidelines and longer follow-up are needed. The experimental process involved the reaction of 4-((2,4-Dichloro-5-methoxyphenyl)amino)-6-methoxy-7-(3-(4-methylpiperazin-1-yl)propoxy)quinoline-3-carbonitrile(cas: 380843-75-4).SDS of cas: 380843-75-4

The Article related to tyrosine kinase inhibitor pediatric philadelphia chromosome leukemia, bcr-abl leukemia, cml, late-effects, ph + all, surveillance, tyrosine kinase inhibitors, Placeholder for records without volume info and other aspects.SDS of cas: 380843-75-4

Referemce:
Piperazine – Wikipedia,
Piperazines – an overview | ScienceDirect Topics

Kazim, Noor; Yen, Andrew published an article in 2021, the title of the article was Evidence of off-target effects of bosutinib that promote retinoic acid-induced differentiation of non-APL AML cells.Safety of 4-((2,4-Dichloro-5-methoxyphenyl)amino)-6-methoxy-7-(3-(4-methylpiperazin-1-yl)propoxy)quinoline-3-carbonitrile And the article contains the following content:

In the present study, we determined the effects of the Src family kinase (SFK) inhibitor, Bosutinib, and the engineered loss of the Lyn SFK on all-trans retinoic acid-induced leukemic cell differentiation. Retinoic acid (RA) is an embryonic morphogen and dietary factor that demonstrates chemotherapeutic efficacy in inducing differentiation of a non-APL AML cell model, the HL-60 human myeloblastic (FAB-M2) leukemia cell line, via activation of a novel signalsome containing an ensemble of signaling mols. that drive differentiation. Bosutinib is an inhibitor of SFKs used to treat myeloid leukemias where prominent high expression of SFKs, in particular Lyn, has been observed Using either Bosutinib or loss of Lyn expression due to shRNA promoted RA-induced phenotypic differentiation, G0 arrest, and respiratory burst (functional differentiation) of HL-60 cells. Signaling events putatively seminal to RA-induced differentiation, the expression of Fgr, Cbl, Slp-76 and Vav, and the phosphorylation of c-Raf (pS259), Vav (p-tyr), and Slp76 (p-tyr) were not inhibited by Bosutinib or loss of Lyn. Nor was RA-induced upregulation of p-tyr phosphorylation of p47phox, a member of the NADPH complex that produces ROS, a putative phosphorylation dependent signaling regulator. Surprisingly, Bosutinib still works in the absence of Lyn to enhance RA-induced differentiation and neither compromised RA-induced expression, nor phosphorylation of signaling mols. that drive differentiation. These findings suggested there is a novel, off-target, Lyn-independent effect of Bosutinib that is of therapeutic significance to differentiation therapy. The experimental process involved the reaction of 4-((2,4-Dichloro-5-methoxyphenyl)amino)-6-methoxy-7-(3-(4-methylpiperazin-1-yl)propoxy)quinoline-3-carbonitrile(cas: 380843-75-4).Safety of 4-((2,4-Dichloro-5-methoxyphenyl)amino)-6-methoxy-7-(3-(4-methylpiperazin-1-yl)propoxy)quinoline-3-carbonitrile

The Article related to bosutinib retinoic acid phosphorylation, acute myeloid leukemia (aml), lyn, bosutinib, cell differentiation, retinoic acid (ra), src family kinase (sfk) inhibitor, Placeholder for records without volume info and other aspects.Safety of 4-((2,4-Dichloro-5-methoxyphenyl)amino)-6-methoxy-7-(3-(4-methylpiperazin-1-yl)propoxy)quinoline-3-carbonitrile

Referemce:
Piperazine – Wikipedia,
Piperazines – an overview | ScienceDirect Topics

Fu, Yuna; Wang, Jianhua; Wang, Yan; Sun, Heng published an article in 2022, the title of the article was Investigating the Effect of Tyrosine Kinase Inhibitors on the Interaction between Human Serum Albumin by Atomic Force Microscopy.Category: piperazines And the article contains the following content:

It is important for elucidating the regulation mechanism of life activities, as well as for the prevention, diagnosis, and drug design of diseases, to study protein-protein interactions (PPIs). Here, we investigated the interactions of human serum albumin (HSA) in the presence of tyrosine kinase inhibitors (TKIs: imatinib, nilotinib, dasatinib, bosutinib, and ponatinib) using at. force microscopy (AFM). The distribution of rupture events including the specific interaction force Fi and the non-specific interaction force F0 between HSA pairs was analyzed. Based on the force measurements, Fi and F0 between HSA pairs in the control experiment were calculated to be 47 ± 1.5 and 116.1 ± 1.3 pN. However, Fi was significantly decreased in TKIs, while F0 was slightly decreased. By measuring the rupture forces at various loading rates and according to the Bell equation, the kinetic parameters of the complexes were investigated in greater detail. Mol. docking was used as a complementary means by which to explore the force of this effect. The whole measurements indicated that TKIs influenced PPIs in a variety of ways, among which hydrogen bonding and hydrophobic interactions were the most important. In conclusion, these outcomes give us a better insight into the mechanisms of PPIs when there are exogenous compounds present as well as in different liquid environments. The experimental process involved the reaction of 4-((2,4-Dichloro-5-methoxyphenyl)amino)-6-methoxy-7-(3-(4-methylpiperazin-1-yl)propoxy)quinoline-3-carbonitrile(cas: 380843-75-4).Category: piperazines

The Article related to tyrosine kinase inhibitor serum albumin atomic force microscopy, atomic force microscopy, human serum albumin, protein–protein interactions, tyrosine kinase inhibitors, Placeholder for records without volume info and other aspects.Category: piperazines

Referemce:
Piperazine – Wikipedia,
Piperazines – an overview | ScienceDirect Topics

On January 4, 2001, Preiss, Michael published a patent.HPLC of Formula: 86393-32-0 The title of the patent was Hydrates of Ciprofloxacin and procedures for their production. And the patent contained the following:

The subjects of the invention are a procedure for the production of hydrates of Ciprofloxacin, new hydrates of Ciprofloxacin, medicaments containing them, and their use for the production of medicaments. The experimental process involved the reaction of 1-Cyclopropyl-6-fluoro-4-oxo-7-(piperazin-1-yl)-1,4-dihydroquinoline-3-carboxylic acid hydrochloride hydrate(cas: 86393-32-0).HPLC of Formula: 86393-32-0

The Article related to ciprofloxacin hydrate production, Pharmaceuticals: Formulation and Compounding and other aspects.HPLC of Formula: 86393-32-0

Referemce:
Piperazine – Wikipedia,
Piperazines – an overview | ScienceDirect Topics

On March 31, 2000, Tsvetkov, Plamen K.; Velikova, Evtimija I; Kafedzhiiski, Stefan K.; Stoyanov, Simeon I; Dimitrova, Silvija S.; Evstatieva, Anka V; Stoyanova, Evgenija K. published a patent.SDS of cas: 86393-32-0 The title of the patent was Composition and method for the preparation of a medicament dosage form. And the patent contained the following:

The invention relates to a composition and method for the preparation of a medicament form based on 1-cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-7-1-(1-piperazinyl)-quinolin-3-carboxylic acid monohydrochloride, known as ciprofloxacin, which is applied as antibacterial medicine in the medical practice. The composition includes: ciprofloxacin hydrochloride monohydrate and lactose monohydrate in ratio 4.93:1, mannitol SD 200, microcrystalline cellulose, sodium starch glycolate, colloid silicon dioxide, talcum and magnesium stearate. The medicamentous form is produced when ciprofloxacin and lactose monohydrate are mixed in a mixer granulator and are homogenized at speeds: 98 r.p.m. for the small blade, and 1500 r.p.m. for the large blade. Sep., the dissolved sodium starch glycolate is added at continuous agitation to the homogenized mixture Granular mass is produced which is dried at 45-50°C to residual moisture of 3% and is calibrated. To the dry granular mass mannitol SD 200, microcrystalline cellulose, sodium starch glycolate, colloid silicon dioxide, talcum and magnesium stearate. The medicamentous form is produced when ciprofloxacin and lactose monohydrate are mixed in a mixer granulator and are homogenized at speeds: 98 r.p.m. for the small blade, and 1500 r.p.m. for the large blade. Sep., the dissolved sodium starch glycolate is added at continuous agitation to the homogenized mixture Granular mass is produced which is dried at 45-50°C to residual moisture of 3% and is calibrated. To the dry granular mass mannitol SD 200, microcrystalline cellulose, colloidal silicon dioxide, talcum and magnesium stearate are added. The mixture produced is homogenized. A water impermeable layer of a film with Opadry is applied. The experimental process involved the reaction of 1-Cyclopropyl-6-fluoro-4-oxo-7-(piperazin-1-yl)-1,4-dihydroquinoline-3-carboxylic acid hydrochloride hydrate(cas: 86393-32-0).SDS of cas: 86393-32-0

The Article related to ciprofloxacin dosage film tablet, Pharmaceuticals: Formulation and Compounding and other aspects.SDS of cas: 86393-32-0

Referemce:
Piperazine – Wikipedia,
Piperazines – an overview | ScienceDirect Topics

On July 17, 2001, Lee, Fang-yu published a patent.Quality Control of 1-Cyclopropyl-6-fluoro-4-oxo-7-(piperazin-1-yl)-1,4-dihydroquinoline-3-carboxylic acid hydrochloride hydrate The title of the patent was Oral antimicrobial formulations of ciprofloxacin. And the patent contained the following:

The invention provides 3 oral ciprofloxacin formulations, with the first formulation comprising 60-75% ciprofloxacin or its salt, 0.3-10% pregelatinized starch as binder, 5-30% lactose as diluent, 1-10% of sodium starch glycolate as disintegrant and 0.5-2% magnesium stearate as lubricant. The second formulation comprises 60-75% ciprofloxacin or its salt, 1-5% polyvinylpyrrolidone as binder, 5-30% lactose as diluent; 1-10% sodium starch glycolate as disintegrant, and 0.5-2% magnesium stearate as lubricant. The third formulation comprises 60-75% ciprofloxacin or salt, 1-8% poly(vinyl alc.) as binder, 5-30% lactose as diluent, 1-10% sodium starch glycolate as disintegrant, and 0.5-2% magnesium stearate as lubricant. The ciprofloxacin, the binder, the diluent, the disintegrant, and the lubricant are first mixed in a dry state to form a powder mixture, followed by mixing with a water-solvent solution to convert the dry powder mixture into a wet powder mixture before grinding and granulating the wet powder mixture into wet granules, which are further dried to form dry granules. The above 3 formulations do not contain cellulose. Thus, tablets contained ciprofloxacin 70, PVP-K30 2, sodium starch glycolate 5, lactose 21, and Mg stearate 2%. The experimental process involved the reaction of 1-Cyclopropyl-6-fluoro-4-oxo-7-(piperazin-1-yl)-1,4-dihydroquinoline-3-carboxylic acid hydrochloride hydrate(cas: 86393-32-0).Quality Control of 1-Cyclopropyl-6-fluoro-4-oxo-7-(piperazin-1-yl)-1,4-dihydroquinoline-3-carboxylic acid hydrochloride hydrate

The Article related to antimicrobial ciprofloxacin oral, Pharmaceuticals: Formulation and Compounding and other aspects.Quality Control of 1-Cyclopropyl-6-fluoro-4-oxo-7-(piperazin-1-yl)-1,4-dihydroquinoline-3-carboxylic acid hydrochloride hydrate

Referemce:
Piperazine – Wikipedia,
Piperazines – an overview | ScienceDirect Topics

On March 20, 2005, Pshenichnikov, V. G.; Frolova, L. V.; Zaripova, Z. I.; Dmitrieva, I. M.; Besh, E. A.; Mokhnacheva, E. V.; Anishchenko, S. S.; Predeina, N. I. published a patent.Category: piperazines The title of the patent was Eye drops and method for obtaining them. And the patent contained the following:

The present innovation deals with medicinal preparations designed as solution and indicated for therapeutic needs. Eye drops contain ciprofloxacin hydrochloride monohydrate equivalent to 0.3% free base, a buffer system that keeps pH within 3.5-5.5 interval, as a conserving agent – benzalkonium chloride and as a stabilizer – the salt of disodium ethylenediamine tetraacetic acid; moreover, their range of osmolality values correspond to 150-450 mM/kg H2O. Eye drops should be obtained by preparing a buffer system in which mannitol should be dissolved followed by the salt of disodium ethylenediamine tetraacetic acid, benzalkonium chloride, and ciprofloxacin hydrochloride. Then one should perform the control for the quality of the obtained solution, which then is filtered by applying sterilizing elements and packed. This innovation provides treatment of eyes at certain desired osmolality. The experimental process involved the reaction of 1-Cyclopropyl-6-fluoro-4-oxo-7-(piperazin-1-yl)-1,4-dihydroquinoline-3-carboxylic acid hydrochloride hydrate(cas: 86393-32-0).Category: piperazines

The Article related to eye drop ciprofloxacin formulation, Pharmaceuticals: Formulation and Compounding and other aspects.Category: piperazines

Referemce:
Piperazine – Wikipedia,
Piperazines – an overview | ScienceDirect Topics

On February 20, 1997, Canovas Soler, Pedro; Delgadillo Duarte, Joaquin; Moreno Rueda, Juan published a patent.Category: piperazines The title of the patent was Aqueous compositions containing ciprofloxacin. And the patent contained the following:

Aqueous compositions for treatment of otitis media with perforation of the tympanic membrane contain the broad-spectrum antibiotic ciprofloxacin.HCl.H2O 0.12-0.6 (equivalent to 0.1-0.5% free base), buffer (pH 4-5) 0.5-3.0, nonionic surface-active agent 0.05-0.3, thickening agent 0.5-2.0 g, and H2O to 100 mL. This solution is packaged in sterile single dosage units without preservatives. Thus, an aqueous solution was prepared containing ciprofloxacin.HCl.H2O 0.40, AcOH 0.45, NaOAc.3H2O 1.20, polysorbate 80 0.19, methylcellulose 1.15, and glycerin 1.62 weight%. The experimental process involved the reaction of 1-Cyclopropyl-6-fluoro-4-oxo-7-(piperazin-1-yl)-1,4-dihydroquinoline-3-carboxylic acid hydrochloride hydrate(cas: 86393-32-0).Category: piperazines

The Article related to ciprofloxacin solution otitis media, Pharmaceuticals: Formulation and Compounding and other aspects.Category: piperazines

Referemce:
Piperazine – Wikipedia,
Piperazines – an overview | ScienceDirect Topics